<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.2d1 20170631//EN" "JATS-journalpublishing1.dtd">
<article xlink="http://www.w3.org/1999/xlink" dtd-version="1.0" article-type="healthcare" lang="en"><front><journal-meta><journal-id journal-id-type="publisher">IJCRR</journal-id><journal-id journal-id-type="nlm-ta">I Journ Cur Res Re</journal-id><journal-title-group><journal-title>International Journal of Current Research and Review</journal-title><abbrev-journal-title abbrev-type="pubmed">I Journ Cur Res Re</abbrev-journal-title></journal-title-group><issn pub-type="ppub">2231-2196</issn><issn pub-type="opub">0975-5241</issn><publisher><publisher-name>Open Science Publishers LLP</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">166</article-id><article-id pub-id-type="doi"/><article-id pub-id-type="doi-url">http://dx.doi.org/10.31782/IJMPS.2017.7101</article-id><article-categories><subj-group subj-group-type="heading"><subject>Healthcare</subject></subj-group></article-categories><title-group><article-title>Cryptosomes: A Novel Promising Drug Delivery System&#13;
</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Dadure</surname><given-names>Kanhaiya M.</given-names></name></contrib><contrib contrib-type="author"><name><surname>Haldar</surname><given-names>Animeshchandra G. M.</given-names></name></contrib></contrib-group><pub-date pub-type="ppub"><day>10</day><month>04</month><year>2017</year></pub-date><volume/><issue/><fpage>1</fpage><lpage>5</lpage><permissions><copyright-statement>This article is copyright of Popeye Publishing, 2009</copyright-statement><copyright-year>2009</copyright-year><license license-type="open-access" href="http://creativecommons.org/licenses/by/4.0/"><license-p>This is an open-access article distributed under the terms of the Creative Commons Attribution (CC BY 4.0) Licence. You may share and adapt the material, but must give appropriate credit to the source, provide a link to the licence, and indicate if changes were made.</license-p></license></permissions><abstract><p>Vesicular drug delivery systems might be a solution to the problem of limited bioavailability and rapid clearance of medications from the body. The four kinds of lipid-based drug delivery techniques include solid-lipid particle system, emulsion-based system, solid lipid tablet, and vesicular system. Cryptosomes are a novel vesicular drug delivery system that may solve some of the shortcomings of classic drug delivery methods, such as high stability, enhanced bioavailability, longer release, and decreased elimination of fast metabolizable drugs, among others. Cryptosome is derived from the Greek terms __ampersandsignldquo;Crypto,__ampersandsignrdquo; which means __ampersandsignldquo;hidden,__ampersandsignrdquo; and __ampersandsignldquo;Soma,__ampersandsignrdquo; which means __ampersandsignldquo;body.__ampersandsignrdquo; It__ampersandsignrsquo;s made up of phospholipids like di-stearoyl phosphatidylethanolamine-polyethylene glycol and di-stearoyl phosphatidylcholine (DSPE-PEG). Vesicular systems refer to the use of vesicles as a carrier or adjuvant in a variety of applications. This research looks at several vesicular drug delivery technologies and emphasises cryptosome__ampersandsignrsquo;s accomplishments in this area. This review will be useful to researchers working in the field of vesicular drug delivery&#13;
</p></abstract><kwd-group><kwd>Vesicular system</kwd><kwd> Drug Delivery</kwd><kwd> Cryptosome</kwd><kwd> Formulation</kwd><kwd> Composition</kwd><kwd> Preparation</kwd></kwd-group></article-meta></front></article>
